Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Patent
• Report
• Software

Filter by year:

Filter from 202620252024202320222021202020192018201720162015201420132012201120102009200820072006 to Filter to 202620252024202320222021202020192018201720162015201420132012201120102009200820072006

---

Search results

• Journal article
  Ghani R, Chrysostomou D, Roberts LA, Pandiaraja M, Marchesi JR, Mullish BHet al., 2024,

  Faecal (or intestinal) microbiota transplant: a tool for repairing the gut microbiome.

  , Gut Microbes, Vol: 16

  Faecal/intestinal microbiota transplant (FMT/IMT) is an efficacious treatment option for recurrent Clostridioides difficile infection, which has prompted substantial interest in FMT's potential role in the management of a much broader range of diseases associated with the gut microbiome. Despite its promise, the success rates of FMT in these other settings have been variable. This review critically evaluates the current evidence on the impact of clinical, biological, and procedural factors upon the therapeutic efficacy of FMT, and identifies areas that remain nebulous. Due to some of these factors, the optimal therapeutic approach remains unclear; for example, the preferred timing of FMT administration in a heavily antibiotic-exposed hematopoietic cell transplant recipient is not standardized, with arguments that can be made in alternate directions. We explore how these factors may impact upon more informed selection of donors, potential matching of donors to recipients, and aspects of clinical care of FMT recipients. This includes consideration of how gut microbiome composition and functionality may strategically inform donor selection criteria. Furthermore, we review how the most productive advances within the FMT space are those where clinical and translational outcomes are assessed together, and where this model has been used productively in recent years to better understand the contribution of the gut microbiome to human disease, and start the process toward development of more targeted microbiome therapeutics.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Bibbò S, Porcari S, Del Vecchio LE, Severino A, Mullish BH, Ianiro G, Gasbarrini A, Cammarota Get al., 2023,

  Gut microbiota and immunotherapy of renal cell carcinoma

  , Human Vaccines & Immunotherapeutics, Vol: 19, ISSN: 2164-5515
  • Publisher Web Link
  • Cite
• Journal article
  Mullish BH, Tohumcu E, Porcari S, Fiorani M, Di Tommaso N, Gasbarrini A, Cammarota G, Ponziani FR, Ianiro Get al., 2023,

  The role of faecal microbiota transplantation in chronic noncommunicable disorders

  , Journal of Autoimmunity, Vol: 141, Pages: 103034-103034, ISSN: 0896-8411
  • Publisher Web Link
  • Cite
• Journal article
  Hvas CL, Keller J, Baunwall SMD, Edwards LA, Ianiro G, Kupcinskas J, Link A, Mullish BH, Satokari R, Sokol H, Terveer E, Vehreshild MJGet al., 2023,

  European academic faecal microbiota transplantation (EURFMT) network: improving the safety and quality of microbiome therapies in Europe

  , Microbiota in Health and Disease, Vol: 5, ISSN: 2704-8845

  Faecal microbiota transplantation (FMT) has evolved from an anecdotally reported last resort for the critically ill to a well-established first-line treatment for patients with recurrent Clostridioides difficile infection (CDI), supported by grade 1a evidence. Given our improved understanding of the intestinal microbiota and how it impacts human health, FMT is now being explored for a range of emerging indications beyond CDI. In light of the rapid emergence of FMT as a novel treatment strategy in medicine, a need for international harmonisation has arisen. Addressing this need, the recently published 5th edition of the Guide to the quality and safety of tissues and cells for human application, issued by the European Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), harbours complete descriptions of the collection, procurement and application of donor faeces as a substance of human origin (SoHO). The proposed revision of the Blood Tissue and Cell Regulation of the European Union (EU) incorporates stool for FMT as a SoHO. This revised regulation will provide a regulatory framework for the future development of donor-derived microbiome therapies. To implement and underpin the safety and quality requirements for FMT in this newly designed legal context, and to facilitate clinical use, collaboration and research, we established the European Academic FMT Network (EurFMT network). The European FMT Registry plays a pivotal role within this network, facilitating its clinical activities and monitoring safety. In this document, we summarise the basis for using donor faeces-derived microbiome therapies as well as the aim and main scope for the EurFMT network.

  • Abstract
  • Cite
• Journal article
  Kragsnaes MS, Blanco JM, Mullish BH, Contreras-Serrano JI, Kjeldsen J, Horn HC, Pedersen JK, Munk HL, Nilsson AC, Salam A, Lewis MR, Chekmeneva E, Kristiansen K, Marchesi JR, Ellingsen Tet al., 2023,

  Small Intestinal Permeability and Metabolomic Profiles in Feces and Plasma Associate With Clinical Response in Patients With Active Psoriatic Arthritis Participating in a Fecal Microbiota Transplantation Trial: Exploratory Findings From the FLORA Trial

  , ACR OPEN RHEUMATOLOGY, Vol: 5, Pages: 583-593
  • Cite
  • Citations: 5
• Journal article
  Yip AYG, King OG, Omelchenko O, Kurkimat S, Horrocks V, Mostyn P, Danckert N, Ghani R, Satta G, Jauneikaite E, Davies FJ, Clarke TB, Mullish BH, Marchesi JR, McDonald JAKet al., 2023,

  Antibiotics promote intestinal growth of carbapenem-resistant <i>Enterobacteriaceae</i> by enriching nutrients and depleting microbial metabolites

  , NATURE COMMUNICATIONS, Vol: 14
  • Cite
  • Citations: 39
• Journal article
  Routy B, Lenehan JG, Miller WH, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M, Ernst S, Logan D, Belanger K, Esfahani K, Richard C, Ninkov M, Piccinno G, Armanini F, Pinto F, Krishnamoorthy M, Figueredo R, Thebault P, Takis P, Magrill J, Ramsay L, Derosa L, Marchesi JR, Parvathy SN, Elkrief A, Watson IR, Lapointe R, Segata N, Haeryfar SMM, Mullish BH, Silverman MS, Burton JP, Maleki Vareki Set al., 2023,

  Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

  , Nature Medicine, Vol: 29, Pages: 2121-2132, ISSN: 1078-8956
  • Publisher Web Link
  • Cite
• Conference paper
  Forlano R, Martinez-Gili L, Blanco JM, Skinner C, Thursz M, Marchesi Jet al., 2023,

  TOP-088 - Altered gut barrier integrity as a mediator of host-microbiome interactions in diabetic patients with advanced Non-alcoholic fatty liver disease

  , EASL Congress 2023, Publisher: Elsevier, Pages: S601-S602, ISSN: 0168-8278
  • Author Web Link
  • Cite
• Conference paper
  Kragsnaes MS, Blanco JM, Mullish B, Contreras-Serrano JI, Horn HC, Munk H, Pedersen JK, Nilsson AC, Kristiansen K, Kjeldsen J, Marchesi J, Ellingsen Tet al., 2023,

  PLASMA METABOLOMIC PROFILES OF PATIENTS WITH ACTIVE PERIPHERAL PSORIATIC ARTHRITIS CAN DIFFERENTIATE TREATMENT RESPONDERS FROM FAILURES: EXPLORATORY FINDINGS FROM THE FLORA TRIAL

  , European Congress of Rheumatology (EULAR), Publisher: BMJ PUBLISHING GROUP, Pages: 467-468, ISSN: 0003-4967
  • Cite
• Journal article
  Churchward MA, Michaud ER, Mullish BH, Miguens Blanco J, Garcia Perez I, Marchesi JR, Xu H, Kao D, Todd KGet al., 2023,

  Short-chain fatty and carboxylic acid changes associated with fecal microbiota transplant communally influence microglial inflammation

  , Heliyon, Vol: 9, Pages: e16908-e16908, ISSN: 2405-8440
  • Publisher Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.